Abstract:Advanced MaterialsVolume 36, Issue 14 2470103 FrontispieceFree Access ACE2 Receptor-Targeted Inhaled Nanoemulsions Inhibit SARS-CoV-2 and Attenuate Inflammatory Responses (Adv. Mater. 14/2024) Hairui Wang, Hairui Wang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorShuang Luo, Shuang Luo Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorMingxin Xie, Mingxin Xie Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorZhao Chen, Zhao Chen State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510182 P. R. ChinaSearch for more papers by this authorYunming Zhang, Yunming Zhang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorZhiqiang Xie, Zhiqiang Xie Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorYongshun Zhang, Yongshun Zhang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorYu Zhang, Yu Zhang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorLan Yang, Lan Yang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorFuhua Wu, Fuhua Wu Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorXiaoyan Chen, Xiaoyan Chen Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorGuangsheng Du, Guangsheng Du Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorJincun Zhao, Jincun Zhao State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510182 P. R. ChinaSearch for more papers by this authorXun Sun, Xun Sun Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this author Hairui Wang, Hairui Wang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorShuang Luo, Shuang Luo Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorMingxin Xie, Mingxin Xie Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorZhao Chen, Zhao Chen State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510182 P. R. ChinaSearch for more papers by this authorYunming Zhang, Yunming Zhang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorZhiqiang Xie, Zhiqiang Xie Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorYongshun Zhang, Yongshun Zhang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorYu Zhang, Yu Zhang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorLan Yang, Lan Yang Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorFuhua Wu, Fuhua Wu Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorXiaoyan Chen, Xiaoyan Chen Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorGuangsheng Du, Guangsheng Du Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this authorJincun Zhao, Jincun Zhao State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510182 P. R. ChinaSearch for more papers by this authorXun Sun, Xun Sun Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 610041 P. R. ChinaSearch for more papers by this author First published: 04 April 2024 https://doi.org/10.1002/adma.202470103AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Graphical Abstract SARS-CoV-2 In article number 2311537 by Jincun Zhao, Xun Sun, and co-workers, a specific ACE2-binding peptide with a superior antiviral activity was identified and used to modified the inhaled nanoemulsions. The inhaled remdesivir nanoemulsions strongly inhibit SARS-CoV-2 not only by blocking the binding of virus to host cells at the cell surface but also restricting virus replication intracellularly. Volume36, Issue14April 4, 20242470103 RelatedInformation

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (adv. Therap. 7/2021)

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses (adv. Mater. 14/2024)

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19

Peptide S4 is an entry inhibitor of SARS-CoV-2 infection

Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry

Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection

Engineered Trimeric ACE2 Binds Viral Spike Protein and Locks It in “Three-Up” Conformation to Potently Inhibit SARS-CoV-2 Infection

Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening

Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2

Bionics Design of Affinity Peptide Inhibitors for SARS-CoV-2 RBD to Block SARS-CoV-2 RBD-ACE2 Interactions

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo

Computational Analysis on the ACE2-derived Peptides for Neutralizing the ACE2 Binding to the Spike Protein of SARS-CoV-2

Recombinant Human ACE2: Potential Therapeutics of SARS-CoV-2 Infection and Its Complication

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants.